Intratumor heterogeneity of ALK-rearrangements and homogeneity of EGFR-mutations in mixed lung adenocarcinoma

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Marino, Federica Zito ^a   Liguori, Giuseppina ^a   Aquino, Gabriella ^a   Mantia, Elvira La ^a   Bosari, Silvano ^b,c   Ferrero, Stefano ^b,c   Rosso, Lorenzo ^c   Gaudioso, Gabriella ^b,c   De Rosa, Nicla ^d   Scrima, Marianna ^e   Martucci, Nicola ^a   Rocca, Antonello La ^a   Normanno, Nicola ^a   Morabito, Alessandro ^a   Rocco, Gaetano ^a   Botti, Gerardo ^a   Franco, Renato ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d AORN Vincenzo Monaldi   (Italy)

^e Grande Ospedale Metropolitano   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRATUMOR HETEROGENEITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ADENOCARCINOMA; ENZYMOLOGY; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84947767065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139264     Document Type: Article

References (37)

1. Cadioli A, Rossi G, Costantini M, Cavazza A, Migaldi M, Colby TV. Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: Analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas. Am J Surg Pathol. 2014 Apr; 38(4):502-9. doi: 10.1097/PAS.0000000000000154 PMID: 24441660
2. Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: Declining for most histologic types among males,increasing among females. Cancer. 1996 Jun 15; 77(12):2464-70. PMID: 8640694
3. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004
4. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb; 6(2):244-85. doi: 10.1097/JTO.0b013e318206a221 PMID: 21252716
5. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups andimplications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011 May; 24(5):653-64. doi: 10.1038/modpathol.2010.232 PMID: 21252858
6. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010 Aug; 34(8):1155-62. doi: 10.1097/PAS.0b013e3181e4ee32 PMID: 20551825
7. Suda K, Sato K, Shimizu S, Tomizawa K, Takemoto T, Iwasaki T, et al. Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. Biomed Res Int. 2014; 2014:645681. doi: 10.1155/2014/645681 PMID: 25371901
8. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007 Feb 10; 25(5):587-95. PMID: 17290067
9. Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer. 2007 Feb 1; 109(3):581-7. PMID: 17186532
10. Sasaki H, Endo K, Yukiue H, Kobayashi Y, Yano M, Fujii Y. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer. Jan; 55(1):129-30. PMID: 17156891
11. Franco R, Rocco G, Marino FZ, Pirozzi G, Normanno N, Morabito A, et al. Anaplastic lymphoma kinase: A glimmer of hope in lung cancer treatment? Expert Rev Anticancer Ther. 2013 Apr; 13(4):407-20. doi: 10.1586/era.13.18 PMID: 23560836
12. Haneda H, Sasaki H, Lindeman N, Kawano O, Endo K, Suzuki E, et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol. 2006 Feb; 36(2):69-75. PMID: 16449241
13. Shim HS, Lee da H, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Societylung adenocarcinoma classification. Arch Pathol Lab Med. 2011 Oct; 135(10):1329-34. doi: 10.5858/arpa.2010-0493-OA PMID: 21970488
14. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008 Jun; 32(6):810-27. doi: 10.1097/PAS.0b013e31815cb162 PMID: 18391747
15. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008 Jan; 3(1):13-7. doi: 10.1097/JTO.0b013e31815e8b60 PMID: 18166835
16. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009 Apr; 22(4):508-15. doi: 10.1038/modpathol.2009.2 PMID: 19234440
17. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4- ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009 Apr 15; 115(8):1723-33. doi: 10.1002/cncr.24181 PMID: 19170230
18. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009 Aug 15; 15(16):5216-23. doi: 10.1158/1078-0432.CCR-09-0802 PMID: 19671850
19. Chaft JE, Rekhtman N, Ladanyi M, Riely GJ. ALK-rearranged lung cancer: Adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol. 2012 Apr; 7(4):768-9. doi: 10.1097/JTO.0b013e31824c9485 PMID: 22425930
20. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010 Mar; 12(2):169-76. doi: 10.2353/jmoldx.2010.090140 PMID: 20093391
21. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in non small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011 Mar; 6(3):459-65. doi: 10.1097/JTO.0b013e318209edb9 PMID: 21278610
22. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA, Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: A tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2010 Oct; 18(5):433-41. doi: 10.1097/PAI.0b013e3181dddb20 PMID: 20485156
23. Andrechek ER, Nevins JR. Mouse models of cancers: Opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med (Berl). 2010 Nov; 88(11):1095-100.
24. Gerashchenko TS, Denisov EV, Litviakov NV, Zavyalova MV, Vtorushin SV, Tsyganov MM, et al. Intratumor heterogeneity: Nature and biological significance. Biochemistry (Mosc). 2013 Nov; 78(11):1201-15.
25. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995 Jun 15; 75(12):2844-52. PMID: 7773933
26. Zhang Y, Li J, Wang R, Li Y, Pan Y, Cai D, et al. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep. 2014 Nov; 24; 4:7163. doi: 10.1038/srep07163 PMID: 25418354
27. Ohashi K, Rai K, Fujiwara Y, Osawa M, Hirano S, Takata K, et al. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Sci. 2008 Sep; 99 (9):1747-53. doi: 10.1111/j.1349-7006.2008.00875.x PMID: 18564139
28. Soh J, Toyooka S, Ichihara S, Asano H, Kobayashi N, Suehisa H, et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol. 2008 Apr; 3(4):340-7. doi: 10.1097/JTO.0b013e318168d20a PMID: 18379350
29. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008 Apr 1; 68 (7):2106-11. doi: 10.1158/0008-5472.CAN-07-5211 PMID: 18381415
30. Tomonaga N, Nakamura Y, Yamaguchi H, Ikeda T, Mizoguchi K, Motoshima K, et al. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer. 2013 Sep; 14(5):521-6. doi: 10.1016/j.cllc.2013.04.005 PMID: 23786997
31. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012; 17 (7):978-85. doi: 10.1634/theoncologist.2011-0385 PMID: 22673630
32. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011 Aug 1; 29(22):2972-7. doi: 10.1200/JCO.2010.33.3906 PMID: 21730270
33. Jakobsen JN, Sørensen JB. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol. 2012 Feb; 69(2):289-99. doi: 10.1007/s00280-011-1791-9 PMID: 22130585
34. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010 Nov 15; 16(22):5581-90. doi: 10.1158/1078-0432.CCR-10-0851 PMID: 21062932
35. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010 Jul 13; 9:188. doi: 10.1186/1476-4598-9-188 PMID: 20624322
36. Popat S, Vieira de Araújo A, Min T, Swansbury J, Dainton M, Wotherspoon A, et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol. 2011 Nov; 6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e PMID: 22005476
37. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, et al. EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 2011 Feb; 71(2):241-3. doi: 10.1016/j.lungcan.2010.11.014 PMID: 21168933